CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 254 filers reported holding CLOVIS ONCOLOGY INC in Q4 2017. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $9,535,000 | -28.1% | 324,650 | +11.3% | 0.32% | -32.9% |
| Q2 2018 | $13,263,000 | +59.6% | 291,689 | +85.3% | 0.48% | +47.2% |
| Q1 2018 | $8,312,000 | -38.6% | 157,415 | -21.0% | 0.33% | -39.4% |
| Q4 2017 | $13,541,000 | -39.8% | 199,138 | -27.0% | 0.54% | -42.6% |
| Q3 2017 | $22,480,000 | +16.7% | 272,813 | +32.7% | 0.94% | +11.7% |
| Q2 2017 | $19,255,000 | +136.5% | 205,649 | +60.9% | 0.84% | +125.5% |
| Q1 2017 | $8,140,000 | – | 127,839 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $45,630,648,000 | 43.63% |
| EcoR1 Capital, LLC | 384,348 | $21,523,000 | 10.89% |
| Palo Alto Investors LP | 2,102,857 | $117,760,000 | 6.91% |
| NEA Management Company, LLC | 2,279,781 | $127,668,000 | 6.19% |
| Redmile Group, LLC | 721,632 | $40,411,000 | 4.40% |
| Opaleye Management Inc. | 140,000 | $7,840,000 | 3.96% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 790,555 | $44,271,000 | 2.63% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 339,327 | $19,002,000 | 2.31% |
| PFM Health Sciences, LP | 1,725,126 | $96,607,000 | 2.26% |
| HARBOURVEST PARTNERS LLC | 51,037 | $2,858,000 | 1.50% |